Related Experiment Videos
Novel radiation sensitizers targeting tissue hypoxia
1Institute for Drug Development, University of Texas Health Science Center, San Antonio, USA.
Oncology (Williston Park, N.Y.)
|November 7, 1999
Summary
Hypoxic tissues resist radiation therapy. New agents like tirapazamine and RSR13 aim to improve radiation effectiveness by increasing oxygen delivery or sensitizing hypoxic cells.
Area of Science:
- Radiation Oncology
- Cancer Biology
- Pharmacology
Background:
- Hypoxic tissues exhibit radioresistance, requiring significantly higher radiation doses for equivalent cytotoxicity compared to well-oxygenated tissues.
- Existing hypoxic cell sensitizers, such as nitroimidazoles, have shown limited therapeutic benefit due to insufficient potency or toxicity at effective concentrations.
Purpose of the Study:
- To review novel therapeutic modalities designed to overcome hypoxic tumor radioresistance.
- To discuss new agents that either enhance oxygen delivery to tumors or sensitize hypoxic cells to radiation therapy.
Main Methods:
- Review of current literature on emerging treatments for hypoxic tissues.
- Focus on agents in early clinical evaluation, including bioreductive agents, targeted sensitizers, and hemoglobin modifiers.
Main Results:
- Several new modalities are under investigation, showing promise in preclinical and early clinical settings.
- These include tirapazamine, gadolinium texaphyrin, RSR13, and modified bovine hemoglobin, each with distinct mechanisms of action.
Conclusions:
- Novel strategies are being developed to address the challenge of hypoxic tumor radioresistance.
- These emerging therapies hold potential for improving treatment outcomes in radiation oncology.